JHL Biotech (Stock Code: 6540.TWO) announced today that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function in cystic […]
Ninlaro (ixazomib), a proteasome inhibitor and the first oral drug of its kind, has been recommended by the National Institute for Health and Care Excellence for use in combination with lenalidomide (Revlimid) and dexamethasone for […]
Furthermore, the company will be able to formulate and manufacture new dosage forms. The expansion includes the addition of four new current good manufacturing practice (cGMP) processing suites and all associated manufacturing support areas. Avista […]
The regulator has cleared the one-time treatment for use in patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Inherited retinal diseases (also known as inherited retinal dystrophies) are a group of rare blinding conditions caused […]
Manufactured from the patient’s own blood, CellProtect is said to be the first drug candidate consisting of autologous ex-vivo activated and expanded natural killer (NK) cells. The company has performed a clinical phase I/II trial […]